
ITR
pA1
ORF3
mp2
E
mp1
bicistronic
pA2
ITR
ORF1
L
ORF2

FIG. 1A



ITR
E1
mp1
pA
L
mp2
E2
ITR
ORF1
ORF2
ORF3

FIG. 1B

FIG 2



IL2 leader imp
c-myc 5'UTR
CMV mp1
Enhancer
CMV mp2
IL2 leader imp
Anti-TSG101 VH
CH'1
CH'2-3
synthetic polyA
ITR
F16 VL
CL
furin
f2a
IL2 leader imp
F16 VH
CH1
CH2-3
TKpAshort
ITR

FIG 3



Mock
pZAC
3bnc117
Fi6v3k2/C05
3.5
3
2.5
2
1.5
1
0.5
0
HA head
HA
HA steam

FIG 4A

3
2.5
2
1.5
1
0.5
0
ctrl
Ab

FIG 4B

1
0.8
0.6
0.4
0.2
0
OD, 450 nm
ctrl
1A6
Dilution
1 to 4
1 to 16
1 to 64

FIG 5



1000.00
100.00
10.00
1.00
0.10
Day 0
Day 7
Day 14
Day 21
Day 28
Day 34
Day 42
Day 49
Day 56
1E11 GC
1E10 GC

FIG 6B



Percent survival
100
50
0
0
10
20
30
Post-infection (days)

FIG 6A



% Change in weight
120
110
100
90
80
70
0
10
20
30
Post-infection (days)

FIG. 7B





Percent survival
100
50
0
0
10
20
30
Post-infection (days)

FIG. 7A


% Change in weight
120
110
100
90
80
70
0
10
20
30
Post-infection (days)


105
100
95
90
85
80
75
70
65
1 2 3 4 5 6 7 8 9 10 11 12 13 14
FI6/TCN MAB 25 ug/ml
FI6/TCN MAB 0.4 ug/ml
FIG 8A
105
100
95
90
85
80
75
70
65
1 2 3 4 5 6 7 8 9 10 11 12 13
FI6/1A6 MABs 263.2 ug/ml
FI6/1A6 MABs 36.5 ug/ml
FIG 8B
110.0
105.0
100.0
95.0
90.0
85.0
80.0
75.0
0 1 2 3 4 5 6 7 8 9 10111213141516171819202 1
FI6/CR8033 MABs 126.3 ug/ml
FI6/CR8033 MABs 6.9 ug/ml
FIG 8C